{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:19:12Z","timestamp":1790392752404,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013295","name":"Helmholtz Zentrum M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013295","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.semcancer.2016.05.002","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T19:01:10Z","timestamp":1464894070000},"page":"3-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Mechanisms of NF-\u03baB deregulation in lymphoid malignancies"],"prefix":"10.1016","volume":"39","author":[{"given":"Daniel","family":"Krappmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Vincendeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semcancer.2016.05.002_bib0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1101\/gad.183434.111","article-title":"NF-kappaB, the first quarter-century: remarkable progress and outstanding questions","volume":"26","author":"Hayden","year":"2012","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0010","doi-asserted-by":"crossref","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","article-title":"The NF-kappaB family of transcription factors and its regulation","volume":"1","author":"Oeckinghaus","year":"2009","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/embr.201337983","article-title":"The IkappaB kinase complex in NF-kappaB regulation and beyond","volume":"15","author":"Hinz","year":"2014","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1600-065X.2012.01107.x","article-title":"IKK biology","volume":"246","author":"Liu","year":"2012","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0025","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","article-title":"The noncanonical NF-kappaB pathway","volume":"246","author":"Sun","year":"2012","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0030","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-065X.2012.01106.x","article-title":"NF-kappaB function in B lymphocytes","volume":"246","author":"Kaileh","year":"2012","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.semcancer.2016.05.002_bib0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/0092-8674(86)90346-6","article-title":"Multiple nuclear factors interact with the immunoglobulin enhancer sequences","volume":"46","author":"Sen","year":"1986","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1128\/JVI.45.1.104-113.1983","article-title":"Structure and expression of c-rel, the cellular homolog to the oncogene of reticuloendotheliosis virus strain T","volume":"45","author":"Chen","year":"1983","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/j.semcancer.2016.05.002_bib0045","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1073\/pnas.80.20.6229","article-title":"Nucleotide sequence of v-rel: the oncogene of reticuloendotheliosis virus","volume":"80","author":"Stephens","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.semcancer.2016.05.002_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/scbi.1997.0061","article-title":"Rel\/NF-kappa B and I kappa B factors in oncogenesis","volume":"8","author":"Luque","year":"1997","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.semcancer.2016.05.002_bib0055","first-page":"M55","article-title":"The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance","volume":"1470","author":"Mayo","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.semcancer.2016.05.002_bib0060","first-page":"2839","article-title":"Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies","volume":"8","author":"Fracchiolla","year":"1993","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0065","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0092-8674(91)90285-7","article-title":"B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50","volume":"67","author":"Neri","year":"1991","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.semcancer.2016.05.002_bib0070","first-page":"1235","article-title":"Alterations at the rel locus in human lymphoma","volume":"6","author":"Lu","year":"1991","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0075","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0092-8674(90)90347-H","article-title":"The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control","volume":"60","author":"Ohno","year":"1990","journal-title":"Cell"},{"issue":"5288","key":"10.1016\/j.semcancer.2016.05.002_bib0080","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1126\/science.274.5288.782","article-title":"An essential role for NF-kappaB in preventing TNF-alpha-induced cell death","volume":"274","author":"Beg","year":"1996","journal-title":"Science (New York, N.Y.)"},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0085","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1128\/MCB.19.4.2690","article-title":"NF-kappaB function in growth control: regulation of cyclin D1 expression and G0\/G1-to-S-phase transition","volume":"19","author":"Hinz","year":"1999","journal-title":"Mol. Cell. Biol."},{"issue":"12","key":"10.1016\/j.semcancer.2016.05.002_bib0090","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1172\/JCI119849","article-title":"Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells","volume":"100","author":"Bargou","year":"1997","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.semcancer.2016.05.002_bib0095","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1182\/blood.V87.10.4340.bloodjournal87104340","article-title":"High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin\/reed-sternberg cells","volume":"87","author":"Bargou","year":"1996","journal-title":"Blood"},{"issue":"49","key":"10.1016\/j.semcancer.2016.05.002_bib0100","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/sj.onc.1203221","article-title":"Aberrant rel\/nfkb genes and activity in human cancer","volume":"18","author":"Rayet","year":"1999","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11899-013-0188-8","article-title":"Bruton's tyrosine kinase (BTK) inhibitors in clinical trials","volume":"9","author":"Burger","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.semcancer.2016.05.002_bib0110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/asheducation.V2012.1.328.3798326","article-title":"New insights in the biology of Hodgkin lymphoma: hematology\/the Education Program of the American Society of Hematology","volume":"2012","author":"Kuppers","year":"2012","journal-title":"Am. Soc. Hematol. Educ. Program"},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0115","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.onc.1202351","article-title":"Molecular mechanisms of constitutive NF-kappaB\/Rel activation in Hodgkin\/Reed-Sternberg cells","volume":"18","author":"Krappmann","year":"1999","journal-title":"Oncogene"},{"issue":"Suppl. 1","key":"10.1016\/j.semcancer.2016.05.002_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/annonc\/13.S1.11","article-title":"Biology of hodgkin's lymphoma","volume":"13","author":"Kuppers","year":"2002","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2016.05.002_bib0125","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V94.9.3129","article-title":"Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells","volume":"94","author":"Emmerich","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semcancer.2016.05.002_bib0130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.1454","article-title":"Inactivating I kappa B epsilon mutations in Hodgkin\/Reed-Sternberg cells","volume":"201","author":"Emmerich","year":"2003","journal-title":"J. Pathol."},{"issue":"2","key":"10.1016\/j.semcancer.2016.05.002_bib0135","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.191.2.395","article-title":"Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma","volume":"191","author":"Jungnickel","year":"2000","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2016.05.002_bib0140","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0145","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.20142009","article-title":"Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia","volume":"212","author":"Mansouri","year":"2015","journal-title":"J. Exp. Med."},{"issue":"7415","key":"10.1016\/j.semcancer.2016.05.002_bib0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"Duhren-von Minden","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0155","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/blood.V99.4.1474","article-title":"Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma","volume":"99","author":"Martin-Subero","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcancer.2016.05.002_bib0160","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/1947601911421925","article-title":"The c-Rel transcription factor in development and disease","volume":"2","author":"Gilmore","year":"2011","journal-title":"Genes Cancer"},{"issue":"27","key":"10.1016\/j.semcancer.2016.05.002_bib0165","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1038\/sj.onc.1210164","article-title":"An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation","volume":"26","author":"Fan","year":"2007","journal-title":"Oncogene"},{"issue":"44","key":"10.1016\/j.semcancer.2016.05.002_bib0170","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.1038\/sj.onc.1206801","article-title":"Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells","volume":"22","author":"Starczynowski","year":"2003","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.semcancer.2016.05.002_bib0175","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/onc.2009.74","article-title":"Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile","volume":"28","author":"Chin","year":"2009","journal-title":"Oncogene"},{"issue":"53","key":"10.1016\/j.semcancer.2016.05.002_bib0180","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1038\/onc.2008.284","article-title":"Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein REL","volume":"27","author":"Leeman","year":"2008","journal-title":"Oncogene"},{"issue":"1\u20133","key":"10.1016\/j.semcancer.2016.05.002_bib0185","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12026-008-8075-4","article-title":"Bcl-3, a multifaceted modulator of NF-kappaB-mediated gene transcription","volume":"42","author":"Palmer","year":"2008","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0190","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2005-09-3843","article-title":"Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma","volume":"108","author":"Martin-Subero","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semcancer.2016.05.002_bib0195","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1038\/leu.2008.102","article-title":"The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia","volume":"22","author":"Chapiro","year":"2008","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.semcancer.2016.05.002_bib0200","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.semcancer.2016.05.002_bib0205","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1182\/blood-2004-03-1037","article-title":"Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling","volume":"104","author":"Bonzheim","year":"2004","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.semcancer.2016.05.002_bib0210","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.semcancer.2016.05.002_bib0215","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2013-06-508028","article-title":"IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL","volume":"122","author":"Nogai","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0220","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.3892\/ijo.2015.3218","article-title":"Induction of IkappaB-zeta by Epstein-Barr virus latent membrane protein-1 and CD30","volume":"47","author":"Ishikawa","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2016.05.002_bib0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"issue":"7247","key":"10.1016\/j.semcancer.2016.05.002_bib0230","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.semcancer.2016.05.002_bib0235","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.semcancer.2016.05.002_bib0240","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1038\/sj.onc.1208564","article-title":"Aberrant NF-kappaB2\/p52 expression in Hodgkin\/Reed-Sternberg cells and CD30-transformed rat fibroblasts","volume":"24","author":"Nonaka","year":"2005","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.semcancer.2016.05.002_bib0245","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood-2012-01-405951","article-title":"Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival","volume":"120","author":"Ranuncolo","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0250","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2141.2012.09113.x","article-title":"Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma","volume":"157","author":"Otto","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"17","key":"10.1016\/j.semcancer.2016.05.002_bib0255","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2016.05.002_bib0260","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1038\/ncomms9428","article-title":"Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth","volume":"6","author":"Vallabhapurapu","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0265","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13073-016-0280-5","article-title":"A roadmap of constitutive NF-kappaB activity in Hodgkin lymphoma: dominant roles of p50 and p52 revealed by genome-wide analyses","volume":"8","author":"de Oliveira","year":"2016","journal-title":"Genome Med."},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0270","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2004.08.009","article-title":"Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase","volume":"21","author":"Ramakrishnan","year":"2004","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.semcancer.2016.05.002_bib0275","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2016.05.002_bib0280","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2015.02.002","article-title":"Lymphomagenesis in hodgkin lymphoma","volume":"34","author":"Matsuki","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"9","key":"10.1016\/j.semcancer.2016.05.002_bib0285","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.semcancer.2016.05.002_bib0290","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.celrep.2015.03.059","article-title":"An oncogenic role for alternative NF-kappaB signaling in DLBCL revealed upon deregulated BCL6 expression","volume":"11","author":"Zhang","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0295","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.semcancer.2016.05.002_bib0305","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.semcancer.2016.05.002_bib0310","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","article-title":"B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells","volume":"94","author":"Seda","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"7354","key":"10.1016\/j.semcancer.2016.05.002_bib0315","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0320","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2016.05.002_bib0325","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-2776(05)87005-1","article-title":"The biology of human lymphoid malignancies revealed by gene expression profiling","volume":"87","author":"Staudt","year":"2005","journal-title":"Adv. Immunol."},{"issue":"7277","key":"10.1016\/j.semcancer.2016.05.002_bib0330","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"7089","key":"10.1016\/j.semcancer.2016.05.002_bib0335","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature04687","article-title":"A loss-of-function RNA interference screen for molecular targets in cancer","volume":"441","author":"Ngo","year":"2006","journal-title":"Nature"},{"issue":"44","key":"10.1016\/j.semcancer.2016.05.002_bib0340","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1073\/pnas.1514944112","article-title":"Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens","volume":"112","author":"Young","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.semcancer.2016.05.002_bib0345","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2016.05.002_bib0350","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaci.2014.06.015","article-title":"The CARD11-BCL10-MALT1;1; (CBM) signalosome complex: stepping into the limelight of human primary immunodeficiency","volume":"134","author":"Turvey","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.semcancer.2016.05.002_bib0355","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1084\/jem.20091167","article-title":"Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells","volume":"206","author":"Ferch","year":"2009","journal-title":"J. Exp. Med."},{"issue":"5870","key":"10.1016\/j.semcancer.2016.05.002_bib0360","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.semcancer.2016.05.002_bib0365","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/gcc.22126","article-title":"Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma","volume":"53","author":"Bohers","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"18","key":"10.1016\/j.semcancer.2016.05.002_bib0370","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2016.05.002_bib0375","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0380","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.molcel.2013.08.032","article-title":"Structural architecture of the CARMA1\/Bcl10\/MALT1 signalosome: nucleation-induced filamentous assembly","volume":"51","author":"Qiao","year":"2013","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.semcancer.2016.05.002_bib0385","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-10-2525","article-title":"Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas","volume":"71","author":"Naylor","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0390","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.semcancer.2016.05.002_bib0395","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1084\/jem.20112744","article-title":"Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production","volume":"209","author":"Jeelall","year":"2012","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2016.05.002_bib0400","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1084\/jem.20120831","article-title":"Congenital B cell lymphocytosis explained by novel germline CARD11 mutations","volume":"209","author":"Snow","year":"2012","journal-title":"J. Exp. Med."},{"issue":"52","key":"10.1016\/j.semcancer.2016.05.002_bib0405","doi-asserted-by":"crossref","first-page":"E7230","DOI":"10.1073\/pnas.1507459112","article-title":"Lymphomagenic CARD11\/BCL10\/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kappaB and JNK activation","volume":"112","author":"Knies","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0410","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ccr.2010.11.024","article-title":"Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma","volume":"18","author":"Calado","year":"2010","journal-title":"Cancer Cell"},{"issue":"7234","key":"10.1016\/j.semcancer.2016.05.002_bib0415","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature07613","article-title":"Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival","volume":"458","author":"Bidere","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2016.05.002_bib0420","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2015.493","article-title":"Oncogenic CARMA1 couples NF-kappaB and beta-catenin signaling in diffuse large B-cell lymphomas","author":"Bognar","year":"2016","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.semcancer.2016.05.002_bib0425","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/sj.emboj.7601897","article-title":"Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation","volume":"26","author":"Oeckinghaus","year":"2007","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.semcancer.2016.05.002_bib0430","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1073\/pnas.0712313105","article-title":"NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation","volume":"105","author":"Wu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"14","key":"10.1016\/j.semcancer.2016.05.002_bib0435","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2013-05-504019","article-title":"A catalytic-independent role for the LUBAC in NF-kappaB activation upon antigen receptor engagement and in lymphoma cells","volume":"123","author":"Dubois","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0440","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2159-8290.CD-13-0915","article-title":"Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms","volume":"4","author":"Yang","year":"2014","journal-title":"Cancer Discovery"},{"issue":"19","key":"10.1016\/j.semcancer.2016.05.002_bib0445","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1111\/febs.12944","article-title":"Met1-linked ubiquitination in immune signalling","volume":"281","author":"Fiil","year":"2014","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0450","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2016.03.006","article-title":"Targeting non-proteolytic protein ubiquitination for the treatment of diffuse large B cell lymphoma","volume":"29","author":"Yang","year":"2016","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.semcancer.2016.05.002_bib0455","first-page":"2463","article-title":"Defective immune responses in mice lacking LUBAC-mediated linear ubiquitination in B cells","volume":"32","author":"Sasaki","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.semcancer.2016.05.002_bib0460","article-title":"The paracaspase MALT1: biological function and potential for therapeutic inhibition","author":"Jaworski","year":"2015","journal-title":"CMLS"},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0465","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ccr.2012.11.003","article-title":"MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo","volume":"22","author":"Fontan","year":"2012","journal-title":"Cancer Cell"},{"issue":"47","key":"10.1016\/j.semcancer.2016.05.002_bib0470","doi-asserted-by":"crossref","first-page":"19946","DOI":"10.1073\/pnas.0907511106","article-title":"Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma","volume":"106","author":"Hailfinger","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0475","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ccr.2012.11.002","article-title":"Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL","volume":"22","author":"Nagel","year":"2012","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0480","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ni.2540","article-title":"The protease activity of the paracaspase MALT1 is controlled by monoubiquitination","volume":"14","author":"Pelzer","year":"2013","journal-title":"Nat. Immunol."},{"issue":"1\u20132","key":"10.1016\/j.semcancer.2016.05.002_bib0485","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmb.2012.02.018","article-title":"Structural determinants of MALT1 protease activity","volume":"419","author":"Wiesmann","year":"2012","journal-title":"J. Mol. Biol."},{"issue":"39","key":"10.1016\/j.semcancer.2016.05.002_bib0490","doi-asserted-by":"crossref","first-page":"10384","DOI":"10.1002\/anie.201304290","article-title":"Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase","volume":"52","author":"Schlauderer","year":"2013","journal-title":"Angewandte Chem."},{"issue":"39","key":"10.1016\/j.semcancer.2016.05.002_bib0495","doi-asserted-by":"crossref","first-page":"42232","DOI":"10.18632\/oncotarget.6273","article-title":"Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma","volume":"6","author":"Nagel","year":"2015","journal-title":"Oncotarget"},{"issue":"7247","key":"10.1016\/j.semcancer.2016.05.002_bib0500","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nature07969","article-title":"Frequent inactivation of A20 in B-cell lymphomas","volume":"459","author":"Kato","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.semcancer.2016.05.002_bib0505","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J. Exp. Med."},{"issue":"35","key":"10.1016\/j.semcancer.2016.05.002_bib0510","doi-asserted-by":"crossref","first-page":"14596","DOI":"10.1073\/pnas.1105020108","article-title":"Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines","volume":"108","author":"Hailfinger","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.semcancer.2016.05.002_bib0515","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.celrep.2015.11.009","article-title":"LUBAC-Recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes","volume":"13","author":"Draber","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2016.05.002_bib0520","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.185025","article-title":"The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling","author":"Douanne","year":"2016","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2016.05.002_bib0525","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/febs.13597","article-title":"MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-kappaB signaling","volume":"283","author":"Elton","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.semcancer.2016.05.002_bib0530","doi-asserted-by":"crossref","first-page":"8777","DOI":"10.1038\/ncomms9777","article-title":"The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-kappaB signalling","volume":"6","author":"Klein","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0535","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.celrep.2014.10.044","article-title":"Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation","volume":"9","author":"Gewies","year":"2014","journal-title":"Cell Rep."},{"issue":"23","key":"10.1016\/j.semcancer.2016.05.002_bib0540","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.15252\/embj.201488987","article-title":"Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity","volume":"33","author":"Jaworski","year":"2014","journal-title":"EMBO J."},{"issue":"11","key":"10.1016\/j.semcancer.2016.05.002_bib0545","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ni.3008","article-title":"Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation","volume":"15","author":"Jeltsch","year":"2014","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.semcancer.2016.05.002_bib0550","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2013.04.034","article-title":"Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation","volume":"153","author":"Uehata","year":"2013","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.semcancer.2016.05.002_bib0555","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.icb.7100097","article-title":"Regulating B-cell activation and survival in response to TLR signals","volume":"85","author":"Gerondakis","year":"2007","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.semcancer.2016.05.002_bib0560","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2014.00367","article-title":"Toll-Like receptors and cancer: MYD88 mutation and inflammation","volume":"5","author":"Wang","year":"2014","journal-title":"Front. Immunol."},{"issue":"7332","key":"10.1016\/j.semcancer.2016.05.002_bib0565","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.semcancer.2016.05.002_bib0570","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/ajh.23545","article-title":"Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia","volume":"88","author":"Poulain","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.semcancer.2016.05.002_bib0575","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-11-684183","article-title":"B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice","author":"Knittel","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.semcancer.2016.05.002_bib0580","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1084\/jem.20151074","article-title":"Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy","volume":"212","author":"Kelly","year":"2015","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2016.05.002_bib0585","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20131424","article-title":"Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance","volume":"211","author":"Wang","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2016.05.002_bib0590","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2013-2332","article-title":"Abstract 2332: oncogenic MYD88 mutants require toll-like receptors","author":"Lim","year":"2013","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0595","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4331\/wjbc.v7.i1.128","article-title":"API2-MALT1 oncoprotein promotes lymphomagenesis via unique program of substrate ubiquitination and proteolysis","volume":"7","author":"Rosebeck","year":"2016","journal-title":"World J. Biol. Chem."},{"issue":"9249","key":"10.1016\/j.semcancer.2016.05.002_bib0600","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)03571-6","article-title":"Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy","volume":"357","author":"Liu","year":"2001","journal-title":"Lancet (London England)"},{"issue":"38","key":"10.1016\/j.semcancer.2016.05.002_bib0605","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1038\/sj.onc.1210342","article-title":"A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment","volume":"26","author":"Lucas","year":"2007","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.semcancer.2016.05.002_bib0610","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2005.04.012","article-title":"Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity","volume":"7","author":"Zhou","year":"2005","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.semcancer.2016.05.002_bib0615","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1074\/jbc.M611038200","article-title":"A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions","volume":"282","author":"Noels","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.semcancer.2016.05.002_bib0620","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1038\/onc.2013.195","article-title":"The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-kappaB signaling","volume":"33","author":"Rosebeck","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0625","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1172\/JCI25641","article-title":"cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas","volume":"116","author":"Hu","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.semcancer.2016.05.002_bib0630","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/0008-5472.CAN-03-3677","article-title":"Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma","volume":"64","author":"Hosokawa","year":"2004","journal-title":"Cancer Res."},{"issue":"6016","key":"10.1016\/j.semcancer.2016.05.002_bib0635","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1198946","article-title":"Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation","volume":"331","author":"Rosebeck","year":"2011","journal-title":"Science (New York N.Y.)"},{"key":"10.1016\/j.semcancer.2016.05.002_bib0640","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/ncomms6908","article-title":"Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma","volume":"6","author":"Nie","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0645","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1476-5381.2011.01608.x","article-title":"Inhibitory kappa B Kinases as targets for pharmacological regulation","volume":"165","author":"Gamble","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.semcancer.2016.05.002_bib0650","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/cr.2010.175","article-title":"NF-kappaB in the regulation of epithelial homeostasis and inflammation","volume":"21","author":"Wullaert","year":"2011","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0655","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13427","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"170","author":"Zhang","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.semcancer.2016.05.002_bib0660","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14728222.2011.548861","article-title":"The kinase NIK as a therapeutic target in multiple myeloma","volume":"15","author":"Gardam","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.semcancer.2016.05.002_bib0665","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccr.2014.07.027","article-title":"Cancer-selective targeting of the NF-kappaB survival pathway with GADD45beta\/MKK7 inhibitors","volume":"26","author":"Tornatore","year":"2014","journal-title":"Cancer Cell"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X16300207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X16300207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T10:56:53Z","timestamp":1600685813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X16300207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":133,"alternative-id":["S1044579X16300207"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2016.05.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726402319.793543968","asserted-by":"object"}]},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of NF-\u03baB deregulation in lymphoid malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2016.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}